What is missing from the anti-B-cell narrative? #ClinicSpeak #MSBlog
Will anti-B-cell therapies become the agents of choice for treating both the relapsing and advanced stages of MS. Another slick video explaining the mode of action of anti-B-cell therapies.
What is missing? I think the narrative in this video is incomplete. Can you spot was is missing?
CoI: multiple, the production of this video has been funded by Roche
Labels: #ClinicSpeak, B-cell, Roche